Cytokinetics Selling General and Administrative Expense Trend from 2010 to 2022

CYTK
 Stock
  

USD 47.25  0.22  0.46%   

Cytokinetics Selling General and Administrative Expense is increasing with slightly volatile movements from year to year. Selling General and Administrative Expense is estimated to finish at about 104.4 M this year. For the period between 2010 and 2022, Cytokinetics, Selling General and Administrative Expense quarterly trend regression had mean deviation of 22,417,386 and r-value of  0.86. Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million.
  
Refresh
Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics main balance sheet or income statement drivers, such as Gross Profit of 59.3 M, Interest Expense of 17.7 M or Operating Expenses of 277 M, as well as many exotic indicators such as Interest Coverage of 7.48, Long Term Debt to Equity of 0.56 or PPandE Turnover of 1.67. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules. It can also supplement various Cytokinetics Technical models. Continue to the analysis of Cytokinetics Correlation against competitors.

Cytokinetics Quarterly Selling General and Administrative Expense

33.07 Million

Share

Cytokinetics Selling General and Administrative Expense Breakdown

Showing smoothed Selling General and Administrative Expense of Cytokinetics with missing and latest data points interpolated. A component of Operating Expenses representing the aggregate total costs related to selling a firm's product and services; as well as all other general and administrative expenses. Direct selling expenses (for example; credit; warranty; and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products; for example telephone expenses; Internet; and postal charges. General and administrative expenses include salaries of non-sales personnel; rent; utilities; communication; etc.Cytokinetics' Selling General and Administrative Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytokinetics' overall financial position and show how it may be relating to other accounts over time.
Selling General and Administrative Expense10 Years Trend
Increasing
Slightly volatile
 Selling General and Administrative Expense 
Share
      Timeline 

Cytokinetics Selling General and Administrative Expense Regression Statistics

Arithmetic Mean 36,991,334
Geometric Mean 28,422,420
Coefficient Of Variation 83.21
Mean Deviation 22,417,386
Median 27,823,000
Standard Deviation 30,780,253
Range 92,016,342
R-Value 0.86
R-Squared 0.74
Significance 0.00014639
Slope 6,819,473

Cytokinetics Selling General and Administrative Expense History

201212.4 M
201315.1 M
201417.3 M
201519.7 M
201627.8 M
201736.5 M
201831.3 M
201939.6 M
202052.8 M
202196.8 M
2022104.4 M

About Cytokinetics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytokinetics income statement, its balance sheet, and the statement of cash flows. Cytokinetics investors use historical funamental indicators, such as Cytokinetics's Selling General and Administrative Expense, to determine how well the company is positioned to perform in the future. Although Cytokinetics investors may use each financial statement separately, they are all related. The changes in Cytokinetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytokinetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytokinetics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytokinetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Selling General and Administrative Expense96.8 M104.4 M
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Cytokinetics Investors Sentiment

The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Cytokinetics Implied Volatility

    
  92.76  
Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.

Current Sentiment - CYTK

Cytokinetics Investor Sentiment

Most of Macroaxis users are currently bullish on Cytokinetics. What is your opinion about investing in Cytokinetics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Continue to the analysis of Cytokinetics Correlation against competitors. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.